2. Search Result
Search Result
Isoforms Recommended: CK1
Results for "

CK1ε

" in MedChemExpress (MCE) Product Catalog:

30

Inhibitors & Agonists

1

Fluorescent Dyes

1

Biochemical Assay Reagents

2

Natural
Products

2

Recombinant Proteins

1

GMP Molecules

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-15490
    PF-670462 dihydrochloride
    Maximum Cited Publications
    8 Publications Verification

    		 Casein Kinase Cancer
    PF-670462 dihydrochloride is a potent and selective inhibitor of casein kinase (CK1ε and CK1δ), with IC50s of 7.7 nM and 14 nM, respectively.
    PF-670462 dihydrochloride
  • HY-12279
    Umbralisib
    5 Publications Verification

    TGR-1202; RP5264

    		 PI3K Casein Kinase Cancer
    Umbralisib (TGR-1202) is an orally active, potent and selective dual PI3Kδ and casein kinase-1-ε (CK1ε) inhibitor, with EC50 of 22.2 nM and 6.0 μM, respectively. Umbralisib exhibits unique immunomodulatory effects on chronic lymphocytic leukemia (CLL) T cells. Umbralisib can be used for haematological malignancies reseach [1] .
    Umbralisib
  • HY-12879
    IWP-4
    2 Publications Verification

    		 Wnt Casein Kinase Cardiovascular Disease Neurological Disease Cancer
    IWP-4 is a Wnt inhibitor with an IC50 of 25 nM. IWP-4 specifically inhibits casein kinase 1δ/ε (CK1δ/ε), with an IC50 of 1.06 μM against wild-type CK1δ, 1.02 μM against the CK1δ kinase domain, and 7.07 μM against CK1ε; it shows enhanced inhibitory activity against the M82F CK1δ mutant (IC50 = 0.14 μM). IWP-4 is applicable to research related to cancer, Alzheimer's disease (AD), and heart failure [1] .
    IWP-4
  • HY-111820
    CK1-IN-1

    		Casein Kinase p38 MAPK Cardiovascular Disease
    CK1-IN-1 (Compound 1c) is a casein kinase 1 (CK1) inhibitor with IC50 values of 15 nM and 16 nM for CK1δ and CK1ε, respectively. CK1-IN-1 inhibits p38α MAPK with an IC50 of 73 nM. CK1-IN-1 can be used to study cardiomyogenesis [1].
    CK1-IN-1
  • HY-100115
    TA-02
    2 Publications Verification

    		 p38 MAPK Autophagy Cardiovascular Disease Inflammation/Immunology Cancer
    TA-02, an analog of SB 203580 (HY-10256), is a p38 MAPK inhibitor with an IC50 of 20 nM. TA-02 especially inhibits TGFBR-2. TA-02 exhibits similar cardiogenic properties as SB 203580 and SB 202190 (HY-10295) [1].
    TA-02
  • HY-100011
    SR-3029
    2 Publications Verification

    		 Casein Kinase Cancer
    SR-3029 is a potent and ATP competitive CK1δ and CK1ε inhibitor, with IC50s of 44 nM and 260 nM, respectively, and Kis of 97 nM for both kinases.
    SR-3029
  • HY-N3127
    Orobol

    		Casein Kinase PI3K VEGFR Metabolic Disease
    Orobol is one of the major soy isoflavones and has various pharmacological activities, including anti-skin-aging and anti-obesity effects. Orobol inhibits CK1ε, VEGFR2, MAP4K5, MNK1, MUSK, TOPK, and TNIK (IC50=1.24-4.45 μM). Orobol also inhibits PI3K isoforms (IC50=3.46-5.27 μM for PI3K α/β/γ/K/δ) [1] .
    Orobol
  • HY-100114
    TA-01

    		Casein Kinase p38 MAPK Autophagy Cardiovascular Disease
    TA-01 is a potent CK1 and p38 MAPK inhibitor, with IC50s of 6.4 nM, 6.8 nM, 6.7 nM for CK1ε, CK1δ and p38 MAPK, respectively. TA-01 acts as a cardiogenic inhibitor.
    TA-01
  • HY-148251
    MU1742

    		Casein Kinase Cancer
    MU1742 is a probe for CK1δ and CK1ε protein kinases [1].
    MU1742
  • HY-100536
    IWP-3

    		Wnt Cancer
    IWP-3 is an potent inhibitor of Wnt production with an IC50 of 40 nM. IWP-3 inhibits Porcupine (Porcn) function thereby blocking palmitoylation of Wnt proteins. IWP-3 inhibits CK1γ3 and CK1ε only moderately and does not inhibit CK1α [1] .
    IWP-3
  • HY-158975
    VRK1/CK1-IN-1

    		Casein Kinase VRK Cancer
    VRK1/CK1-IN-1 (compound 36) is a dual VRK1 and CK1 family inhibitor, with a Ki of 37.9 nM against human VRK1, 8.3 nM against human CK1δ, and 7.8 nM against human CK1ε. VRK1/CK1-IN-1 exhibits extremely low activity against VRK2. VRK1/CK1-IN-1 can be used in studies related to p53-deficient tumors [1].
    VRK1/CK1-IN-1
  • HY-12279C
    Umbralisib hydrochloride
    5 Publications Verification

    TGR-1202 hydrochloride; RP5264 hydrochloride

    		 PI3K Casein Kinase Cancer
    Umbralisib (TGR-1202) hydrochloride is an orally active, potent and selective dual PI3Kδ and casein kinase-1-ε (CK1ε) inhibitor, with EC50 of 22.2 nM and 6.0 μM, respectively. Umbralisib hydrochloride exhibits unique immunomodulatory effects on chronic lymphocytic leukemia (CLL) T cells. Umbralisib hydrochloride can be used for haematological malignancies reseach [1] .
    Umbralisib hydrochloride
  • HY-170859
    AH078

    		PROTACs Casein Kinase Cancer
    AH078 is a PROTAC-based CK1δ/ε degrader (DC50=0.55 μM, Dmax=70%) that lacks subtype selectivity between CK1δ and CK1ε. AH078 induces target protein degradation either by recruiting the CUL4-CRBN E3 ligase complex and proteasome, or via the VHL- and ubiquitin-dependent pathway. AH078 also exhibits selectivity for CK1α, and is widely applicable to research related to colon cancer, pancreatic cancer, breast cancer, ovarian cancer, chronic lymphocytic leukemia, acute myeloid leukemia, glioma, and metastatic breast adenocarcinoma [1] .
    AH078
  • HY-N6841
    Rhodiolin
    1 Publications Verification

    		 Glucose-6-Phosphate Isomerase (GPI) Casein Kinase Virus Protease Flavivirus PI3K Akt mTOR Apoptosis Infection Cancer
    Rhodiolin, a flavonoid, is an orally active glucose 6-phosphate isomerase (GPI) inhibitor. Rhodiolin inhibits papillary thyroid cancer (PTC) by targeting glycolysis enzyme glucose 6-phosphate isomerase GPI and suppressing PI3K/AKT/mTOR phosphorylation and induce apoptosis. Rhodiolin as a NS2B-NS3 protease inhibitor can disrupt dengue viral replication. Rhodiolin is also a potential candidate for developing anticancer strategies inhibiting CK1ε kinase. Rhodiolin can be used for the study of anti-tumor and anti-viral [1] .
    Rhodiolin
  • HY-108907
    SR-1277

    		Casein Kinase Cancer
    SR-1277 is a potent, selective and ATP competitive CK1δ/ε inhibitor, with IC50s of 49 nM and 260 nM, respectively. SR-1277 also inhibits FLT3, CDK4/cyclin D1, CDK6/cyclin D3 and CDK9/cyclin K, with IC50s of 305 nM, 1340 nM, 311 nM and 109 nM, respectively. SR-1277 can be used for the research of cancer [1].
    SR-1277
  • HY-149292
    SR-4133

    		Casein Kinase Cancer
    SR-4133 is a potent and highly CK1ε selective inhibitor with an IC50 of 58 nM. SR-4133 binds to the ATP-binding site of CK1ε. SR-4133 displays nanomolar growth inhibition of bladder cancer cells, and inhibits the phosphorylation of 4E-BP1 [1].
    SR-4133
  • HY-170860
    CK1δ/CK1ε liagnd-1

    		Ligands for Target Protein for PROTAC Casein Kinase Cancer
    CK1δ/CK1ε liagnd-1 is the ligand for CK1δ/CK1ε that can be used for synthesis of CK1 PROTAC degrader AH078 (HY-170859) as the ligand for target protein [1].
    CK1δ/CK1ε liagnd-1
  • HY-100011R
    SR-3029 (Standard)

    		Casein Kinase Reference Standards Cancer
    SR-3029 (Standard) is the analytical standard of SR-3029 (HY-100011). This product is intended for research and analytical applications. SR-3029 is a potent and ATP competitive CK1δ and CK1ε inhibitor, with IC50s of 44 nM and 260 nM, respectively, and Kis of 97 nM for both kinases.
    SR-3029 (Standard)
  • HY-171278
    Casein kinase 1δ-IN-28

    		Casein Kinase Metabolic Disease Cancer
    Casein kinase 1δ-IN-28 (Compound 4) is the inhibitor for CK1ε with an IC50 of 0.0146 μM. Casein kinase 1δ-IN-28 exhibits a metabolite rate in human liver microsomes of 52% [1].
    Casein kinase 1δ-IN-28
  • HY-170862
    E3 Ligase Ligand-linker Conjugate 163

    		E3 Ligase Ligand-Linker Conjugates Cancer
    E3 Ligase Ligand-linker Conjugate 163 is the E3 ligase ligand (E3 ligase Ligand 58, HY-170861)-linker conjugate part of AH078 (HY-170859). AH078 is a PROTAC that targets the degradation of CK1δ and CK1ε, and can be used for research related to circadian rhythm disorders [1].
    E3 Ligase Ligand-linker Conjugate 163
  • HY-171277
    Casein kinase 1δ-IN-27

    		Casein Kinase p38 MAPK Cancer
    Casein kinase 1δ-IN-27 (Compound 8) is the inhibitor for casein kinase 1 that inhibits CK1α, CK1δ, CK1ε, and p38α with IC50s of 22, 16.5, 9.41 and 14.8 nM, respectively. Casein kinase 1δ-IN-27 inhibits the DUX4 expression with an IC50 of 10 nM [1].
    Casein kinase 1δ-IN-27
  • HY-12279A
    Umbralisib tosylate

    TGR-1202 tosylate; RP5264 tosylate

    		 PI3K Casein Kinase Cancer
    Umbralisib (TGR-1202) tosylate is an orally active, potent and selective dual PI3Kδ and casein kinase-1-ε (CK1ε) inhibitor, with EC50 of 22.2 nM and 6.0 μM, respectively. Umbralisib tosylate exhibits unique immunomodulatory effects on chronic lymphocytic leukemia (CLL) T cells. Umbralisib tosylate can be used for haematological malignancies reseach [1] .
    Umbralisib tosylate
  • HY-12279B
    Umbralisib sulfate

    TGR-1202 sulfate; RP-5264 sulfate

    		 PI3K Casein Kinase Cancer
    Umbralisib (TGR-1202) sulfate is an orally active, potent and selective dual PI3Kδ and casein kinase-1-ε (CK1ε) inhibitor, with EC50 of 22.2 nM and 6.0 μM, respectively. Umbralisib sulfate exhibits unique immunomodulatory effects on chronic lymphocytic leukemia (CLL) T cells. Umbralisib sulfate can be used for haematological malignancies reseach [1] .
    Umbralisib sulfate
  • HY-12279CR
    Umbralisib hydrochloride (Standard)

    TGR-1202 hydrochloride (Standard); RP5264 hydrochloride (Standard)

    		 PI3K Casein Kinase Reference Standards Cancer
    Umbralisib (hydrochloride) (Standard) is the analytical standard of Umbralisib (hydrochloride). This product is intended for research and analytical applications. Umbralisib (TGR-1202) hydrochloride is an orally active, potent and selective dual PI3Kδ and casein kinase-1-ε (CK1ε) inhibitor, with EC50 of 22.2 nM and 6.0 μM, respectively. Umbralisib hydrochloride exhibits unique immunomodulatory effects on chronic lymphocytic leukemia (CLL) T cells. Umbralisib hydrochloride can be used for haematological malignancies reseach [1] .
    Umbralisib hydrochloride (Standard)
  • HY-171279
    Casein kinase 1δ-IN-29

    		p38 MAPK Casein Kinase Apoptosis Inflammation/Immunology
    Casein kinase 1δ-IN-29 (Compound 18) is the inhibitor for p38α and casein kinase 1 that inhibits p38α, CK1δ and CK1ε with IC50 of 0.041 µM, 0.005 µM and 0.447 µM, respectively. Casein kinase 1δ-IN-29 arrests cell cycle at subG1 phase, induces apoptosis in cell AC1-M88 [1].
    Casein kinase 1δ-IN-29
  • HY-12279R
    Umbralisib (Standard)

    TGR-1202 (Standard); RP5264 (Standard)

    		 PI3K Casein Kinase Reference Standards Cancer
    Umbralisib (Standard) is the analytical standard of Umbralisib. This product is intended for research and analytical applications. Umbralisib (TGR-1202) is an orally active, potent and selective dual PI3Kδ and casein kinase-1-ε (CK1ε) inhibitor, with EC50 of 22.2 nM and 6.0 μM, respectively. Umbralisib exhibits unique immunomodulatory effects on chronic lymphocytic leukemia (CLL) T cells. Umbralisib can be used for haematological malignancies reseach [1] .
    Umbralisib (Standard)
  • HY-135629
    PF-5236216

    		Casein Kinase Neurological Disease
    PF-5236216 is a brain-penetrant CK1δ/CK1ε inhibitor with IC50 values of 8 and 36 nM. PF-5236216 inhibits CK1δ and CK1ε-mediated PER3 nuclear translocation. PF-5236216 forms an H-bond with the backbone NH of Leu85, hydrophobic stacking with Met82, and a water-mediated H-bond with Lys38 of CK1δ. PF-5236216 can be used as a tool ligand for CNS PET studies [1].
    PF-5236216
  • HY-123859
    SR-2890

    		Casein Kinase FLT3 CDK Neurological Disease Inflammation/Immunology Cancer
    SR-2890 is a highly selective, ATP-competitive inhibitor of casein kinase CK1δ and CK1ε, with IC50 values ​​of 4 nM and 44 nM, respectively, and a Ki of 14 nM for CK1δ. SR-2890 exhibits antiproliferative effects. SR-2890 blocks the serine/threonine kinase activity of CK1δ and weakly inhibits a few off-target kinases such as FLT3, CDK4. SR-2890 has an oral bioavailability of 10% and a blood-brain barrier penetration rate of <1%. SR-2890 demonstrates stable in vitro metabolism and favorable in vivo pharmacokinetic properties, effectively inhibiting the growth of human A375 melanoma cells. SR-2890 can be used in melanoma research and is also a useful compound for studying CK1δ/ε-related diseases such as Alzheimer's disease [1].
    SR-2890
  • HY-12879G
    IWP-4

    		Wnt Casein Kinase Cardiovascular Disease Neurological Disease Cancer
    IWP-4 (GMP) is the GMP-grade form of IWP-4 (HY-12879). IWP-4 is a Wnt inhibitor with an IC50 of 25 nM. IWP-4 specifically inhibits casein kinase 1δ/ε (CK1δ/ε), with an IC50 of 1.06 μM against wild-type CK1δ, 1.02 μM against the CK1δ kinase domain, and 7.07 μM against CK1ε; it shows enhanced inhibitory activity against the M82F CK1δ mutant (IC50 = 0.14 μM). IWP-4 is applicable to research related to cancer, Alzheimer's disease (AD), and heart failure [1] .
    IWP-4
  • HY-100115R
    TA-02 (Standard)

    		p38 MAPK Reference Standards Autophagy Cardiovascular Disease Inflammation/Immunology Cancer
    TA-02 (Standard) is the analytical standard of TA-02 (HY-100115). This product is intended for research and analytical applications. TA-02, an analog of SB 203580 (HY-10256), is a p38 MAPK inhibitor with an IC50 of 20 nM. TA-02 especially inhibits TGFBR-2. TA-02 exhibits similar cardiogenic properties as SB 203580 and SB 202190 (HY-10295) [1].
    TA-02 (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: